A Single-Center, Double-Blind, Placebo-Controlled, Randomized Blocks Study Investigating the Effect of 4 Dosages (1 mg, 5 mg, 15 mg, 50 mg) of MEM 3454 on P50 Sensory Gating and Mismatch Negativity (MMN) in Patients With Schizophrenia

Trial Profile

A Single-Center, Double-Blind, Placebo-Controlled, Randomized Blocks Study Investigating the Effect of 4 Dosages (1 mg, 5 mg, 15 mg, 50 mg) of MEM 3454 on P50 Sensory Gating and Mismatch Negativity (MMN) in Patients With Schizophrenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs RG 3487 (Primary)
  • Indications Schizophrenia
  • Focus Biomarker; Therapeutic Use
  • Sponsors Memory Pharmaceuticals; Roche
  • Most Recent Events

    • 24 Dec 2008 Results are expected in the third quarter of 2009, according to a Memory Pharmaceuticals media release.
    • 24 Dec 2008 Status changed from planning to recruiting according to a Memory Pharmaceuticals media release.
    • 24 Dec 2008 New source identified and integrated (Memory Pharmaceuticals media release).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top